CTRI/2023/01/048699已完成4 期
A Multi-Center, Prospective, Open label, Single Arm, Post Market Surveillance Study to Evaluate the Safety & Efficacy of Sterile Collagen Particles (fish origin) [Represented by brand names: Biofil and Biocollaz, in healing of non infected or infection cleared Chronic Foot ulcers (diabetic foot ulcers)
Eucare Pharmaceuticals P Ltd0 个研究点目标入组 105 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Male/ female patient more than 18 years and less than70 years of age.
- •2.Patient who can and willing to provide written Informed Consent.
- •3.Patient with Chronic foot ulcers (diabetic foot ulcers) which extend into the papillary (shallow) dermis, or into the reticular (deep) dermis, or into subcutaneous fat, but not extending into muscle, tendon, capsule, or bone.
- •4.Patients with HbA1c less than 8.5%.
- •5.Index ulcer (i.e., current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit and less than 1 year.
- •6.Index ulcer is a minimum of 1 cm2 and a maximum of 25cm2 at first treatment visit.
- •7.The index ulcer has been offloaded for at least 7 days prior to enrolment.
- •8.Patient understands and is willing to participate in the clinical study and can comply with regular treatment visits and the follow-up regimen.
排除标准
- •1. Patient with known allergy/hypersensitivity to collagen or other fish derived products.
- •2. Patient having a medical or social condition that would, in the opinion of the investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol.
- •3. Patient has participated in another clinical study involving another investigational agent within 4 weeks of the start of this trial, or is planning participation in another clinical trial during the current study duration.
- •4. Patients treated with wound dressings that include growth factors, bioengineered tissues, or skin substitutes other than the study material, within 30 days of the screening visit and throughout the study.
- •5. Patients with a history of more than two weeks treatment with immunosuppressants, cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first screening visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
- •6. Presence of any condition(s) which seriously compromises the patient’s ability to complete this study or has a known history of poor adherence with medical treatment.
- •7. Presence of necrosis, purulence, or sinus tracts that cannot be removed by debridement.
- •8. Conditions which will interfere the wound healing process are malignancy, connective tissues disorders, immune system disease.
- •9. Patient with suspected osteomyelitis prior to enrolment.
- •10. Pregnant or lactating females.
- •11. Patient unwilling or unable to comply with the study requirement for offloading the index ulcer.
- •12. Index ulcer has reduced in area by >20% within 2 weeks prior to enrolment
研究者
相似试验
已完成
4 期
A Clinical trial to measure the Safety & Efficacy of Silicone Gel Sheet for Scar ManagementCTRI/2021/04/032491Eucare Pharmaceuticals Private Limited105
已完成
4 期
A clinical trial to study the effects of study product (Gelatin Sponge) in Controlling Bleeding during Intraoperative ProceduresCTRI/2020/10/028681Eucare Pharmaceuticals Private Limited150
已完成
4 期
Post Market Study to Evaluate the Safety & Efficacy of product UrgoClean Ag in the Management of Diabetic Foot UlcersCTRI/2020/12/029670Eucare Pharmaceuticals Private Limited60
尚未招募
不适用
Study to Evaluate Safety and Clinical Performance of Medispine/Glospine Spinal Needle in Patients who Required Spinal Anesthesia.CTRI/2021/09/036398Global Medikit Ltd
招募中
不适用
Study of bortezomib/dexamethasone therapy in patients with relapsed and/or refractory cutaneous T-cell lymphomaKCT0002953Samsung Medical Center32